These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 20524038)

  • 1. Cell death induction in resting lymphocytes by pan-Cdk inhibitor, but not by Cdk4/6 selective inhibitor.
    Kobayashi M; Takahashi-Suzuki I; Shimomura T; Iwasawa Y; Hirai H
    Invest New Drugs; 2011 Oct; 29(5):921-31. PubMed ID: 20524038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ibulocydine is a novel prodrug Cdk inhibitor that effectively induces apoptosis in hepatocellular carcinoma cells.
    Cho SJ; Kim YJ; Surh YJ; Kim BM; Lee SK
    J Biol Chem; 2011 Jun; 286(22):19662-71. PubMed ID: 21478145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia.
    Chen R; Wierda WG; Chubb S; Hawtin RE; Fox JA; Keating MJ; Gandhi V; Plunkett W
    Blood; 2009 May; 113(19):4637-45. PubMed ID: 19234140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of the cyclin-dependent kinases at the beginning of human cytomegalovirus infection specifically alters the levels and localization of the RNA polymerase II carboxyl-terminal domain kinases cdk9 and cdk7 at the viral transcriptosome.
    Kapasi AJ; Spector DH
    J Virol; 2008 Jan; 82(1):394-407. PubMed ID: 17942543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human cytomegalovirus infection induces specific hyperphosphorylation of the carboxyl-terminal domain of the large subunit of RNA polymerase II that is associated with changes in the abundance, activity, and localization of cdk9 and cdk7.
    Tamrakar S; Kapasi AJ; Spector DH
    J Virol; 2005 Dec; 79(24):15477-93. PubMed ID: 16306619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BAY 1000394, a novel cyclin-dependent kinase inhibitor, with potent antitumor activity in mono- and in combination treatment upon oral application.
    Siemeister G; Lücking U; Wengner AM; Lienau P; Steinke W; Schatz C; Mumberg D; Ziegelbauer K
    Mol Cancer Ther; 2012 Oct; 11(10):2265-73. PubMed ID: 22821149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative genomics of cyclin-dependent kinases suggest co-evolution of the RNAP II C-terminal domain and CTD-directed CDKs.
    Guo Z; Stiller JW
    BMC Genomics; 2004 Sep; 5():69. PubMed ID: 15380029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating Chemical CDK Inhibitors as Cell Death Inducers.
    Hirai H; Nakatsuru Y
    Methods Mol Biol; 2016; 1336():167-78. PubMed ID: 26231716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of post-transcriptional RNA processing by CDK inhibitors and its implication in anti-viral therapy.
    Holcakova J; Muller P; Tomasec P; Hrstka R; Nekulova M; Krystof V; Strnad M; Wilkinson GW; Vojtesek B
    PLoS One; 2014; 9(2):e89228. PubMed ID: 24586613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Flavopiridol induces phosphorylation of AKT in a human glioblastoma cell line, in contrast to siRNA-mediated silencing of Cdk9: Implications for drug design and development.
    Caracciolo V; Laurenti G; Romano G; Carnevale V; Cimini AM; Crozier-Fitzgerald C; Gentile Warschauer E; Russo G; Giordano A
    Cell Cycle; 2012 Mar; 11(6):1202-16. PubMed ID: 22391209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment.
    Patel H; Periyasamy M; Sava GP; Bondke A; Slafer BW; Kroll SHB; Barbazanges M; Starkey R; Ottaviani S; Harrod A; Aboagye EO; Buluwela L; Fuchter MJ; Barrett AGM; Coombes RC; Ali S
    Mol Cancer Ther; 2018 Jun; 17(6):1156-1166. PubMed ID: 29545334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity.
    Ali S; Heathcote DA; Kroll SH; Jogalekar AS; Scheiper B; Patel H; Brackow J; Siwicka A; Fuchter MJ; Periyasamy M; Tolhurst RS; Kanneganti SK; Snyder JP; Liotta DC; Aboagye EO; Barrett AG; Coombes RC
    Cancer Res; 2009 Aug; 69(15):6208-15. PubMed ID: 19638587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-talk among RNA polymerase II kinases modulates C-terminal domain phosphorylation.
    Devaiah BN; Singer DS
    J Biol Chem; 2012 Nov; 287(46):38755-66. PubMed ID: 23027873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three cyclin-dependent kinases preferentially phosphorylate different parts of the C-terminal domain of the large subunit of RNA polymerase II.
    Pinhero R; Liaw P; Bertens K; Yankulov K
    Eur J Biochem; 2004 Mar; 271(5):1004-14. PubMed ID: 15009212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Binding to DNA of the RNA-polymerase II C-terminal domain allows discrimination between Cdk7 and Cdk9 phosphorylation.
    Lolli G
    Nucleic Acids Res; 2009 Mar; 37(4):1260-8. PubMed ID: 19136461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00.
    Joshi KS; Rathos MJ; Joshi RD; Sivakumar M; Mascarenhas M; Kamble S; Lal B; Sharma S
    Mol Cancer Ther; 2007 Mar; 6(3):918-25. PubMed ID: 17363486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent anti-tumor activity of a macrocycle-quinoxalinone class pan-Cdk inhibitor in vitro and in vivo.
    Hirai H; Takahashi-Suziki I; Shimomura T; Fukasawa K; Machida T; Takaki T; Kobayashi M; Eguchi T; Oki H; Arai T; Ichikawa K; Hasako S; Kodera T; Kawanishi N; Nakatsuru Y; Kotani H; Iwasawa Y
    Invest New Drugs; 2011 Aug; 29(4):534-43. PubMed ID: 20084424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclin-dependent kinase 7 controls mRNA synthesis by affecting stability of preinitiation complexes, leading to altered gene expression, cell cycle progression, and survival of tumor cells.
    Kelso TW; Baumgart K; Eickhoff J; Albert T; Antrecht C; Lemcke S; Klebl B; Meisterernst M
    Mol Cell Biol; 2014 Oct; 34(19):3675-88. PubMed ID: 25047832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meriolins, a new class of cell death inducing kinase inhibitors with enhanced selectivity for cyclin-dependent kinases.
    Bettayeb K; Tirado OM; Marionneau-Lambot S; Ferandin Y; Lozach O; Morris JC; Mateo-Lozano S; Drueckes P; Schächtele C; Kubbutat MH; Liger F; Marquet B; Joseph B; Echalier A; Endicott JA; Notario V; Meijer L
    Cancer Res; 2007 Sep; 67(17):8325-34. PubMed ID: 17804748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer.
    Frame S; Saladino C; MacKay C; Atrash B; Sheldrake P; McDonald E; Clarke PA; Workman P; Blake D; Zheleva D
    PLoS One; 2020; 15(7):e0234103. PubMed ID: 32645016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.